Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) EPS (Diluted) : $-10.35 (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Corbus Pharmaceuticals Holdings EPS (Diluted)?

Corbus Pharmaceuticals Holdings's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-1.79. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.35.

Corbus Pharmaceuticals Holdings's EPS (Basic) for the three months ended in Dec. 2023 was $-1.79. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.35.

Corbus Pharmaceuticals Holdings's EPS without NRI for the three months ended in Dec. 2023 was $-1.80. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.35.

During the past 3 years, the average EPS without NRIGrowth Rate was 37.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 26.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was -20.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Corbus Pharmaceuticals Holdings's highest 3-Year average EPS without NRI Growth Rate was 37.50% per year. The lowest was -175.80% per year. And the median was -30.60% per year.

Corbus Pharmaceuticals Holdings EPS (Diluted) Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings EPS (Diluted) Chart

Corbus Pharmaceuticals Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-33.60

-42.60

-11.15

-10.15

-10.31

Corbus Pharmaceuticals Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial															-2.61	-4.24	-2.05	-2.27	-1.79

Competitive Comparison of Corbus Pharmaceuticals Holdings's EPS (Diluted)

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corbus Pharmaceuticals Holdings's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's PE Ratio falls into.

Corbus Pharmaceuticals Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Corbus Pharmaceuticals Holdings's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-44.603	-	0)	/	4.328
	=	-10.31

Corbus Pharmaceuticals Holdings's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-8.021	-	0)	/	4.425
	=	-1.81

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.35

Corbus Pharmaceuticals Holdings (NAS:CRBP) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Corbus Pharmaceuticals Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (NAS:CRBP) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

3371:Germany

Address

500 River Ridge Drive, Norwood, MA, USA, 02062

Website

https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.

Executives

Yong Ben	director	500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Anne Altmeyer	director	500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Yuval Cohen	director, officer: Chief Executive Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Craig Stuart Millian	officer: Chief Commercial Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Sean F. Moran	officer: Chief Financial Officer	10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Rachael Louise Brake	officer: Chief Scientific Officer	21 MANCHESTER PLACE, NATICK MA 01760
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Peter Salzmann	director	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Barbara White	officer: Chief Medical Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Paul Discordia	officer: Chief Operating Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
David P Hochman	director	15 WESTON HILL RD., RIVERSIDE CT 06878
John Kenneth Jenkins	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Paris Panayiotopoulos	director	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alan F Holmer	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062